LYU Huizhen
Department of Physiology and Pathophysiology, Tianjin Medical University & Tianjin Key Laboratory of Metabolic Diseases, Tianjin 300070, China;Hospital of Hematology, Chinese Academy of Medical Sciences & Institute of Hematology, Chinese Academy of Medical Sciences & State Key Laboratory of Experimental Hematology, Tianjin 300020, ChinaLI Kan
Department of Physiology and Pathophysiology, Tianjin Medical University & Tianjin Key Laboratory of Metabolic Diseases, Tianjin 300070, ChinaAI Ding
Department of Physiology and Pathophysiology, Tianjin Medical University & Tianjin Key Laboratory of Metabolic Diseases, Tianjin 300070, China;Hospital of Hematology, Chinese Academy of Medical Sciences & Institute of Hematology, Chinese Academy of Medical Sciences & State Key Laboratory of Experimental Hematology, Tianjin 300020, China1.Department of Physiology and Pathophysiology, Tianjin Medical University & Tianjin Key Laboratory of Metabolic Diseases, Tianjin 300070, China;2.Hospital of Hematology, Chinese Academy of Medical Sciences & Institute of Hematology, Chinese Academy of Medical Sciences & State Key Laboratory of Experimental Hematology, Tianjin 300020, China)
LYU Huizhen, LI Kan, AI Ding. Role and application of integrin:a new therapeutic target for cardiovascular disease[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2021,29(2):98-105.
Copy